# Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

> **NCT02039336** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 35 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Dacomitinib
- **DRUG:** PD-0325901
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02039336
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-02
- **Primary completion:** 2018-08-07
- **Final completion:** 2018-08-07
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02039336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02039336, "Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02039336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*